VR
$18.44
+0.04
(+0.22%)
As of Oct 20, 2026, 12:57 PM EDT
Price history
Varex Imaging Corp (VREX) is trading up at $18.44 (+0.22%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Varex Imaging Corp revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Sep 2016 | FY2017Sep 2017 | FY2018Sep 2018 | FY2019Sep 2019 | FY2020Oct 2020 | FY2021Oct 2021 | FY2022Sep 2022 | FY2023Sep 2023 | FY2024Sep 2024 | FY2025Oct 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $620.1M | $698.1M | $773.4M | $780.6M | $738.3M | $818.1M | $859.4M | $893.4M | $811.0M | $844.6M |
| Growth (year over year) | −1.9% | +12.6% | +10.8% | +0.9% | −5.4% | +10.8% | +5.0% | +4.0% | −9.2% | +4.1% |
| Gross profit | $248.4M | $253.5M | $253.9M | $256.7M | $190.2M | $271.5M | $283.5M | $290.3M | $256.9M | $290.5M |
| Gross margin | 40.1% | 36.3% | 32.8% | 32.9% | 25.8% | 33.2% | 33.0% | 32.5% | 31.7% | 34.4% |
| Operating income | $109.1M | $83.7M | $44.5M | $45.7M | −$33.7M | $74.1M | $88.2M | $77.1M | $32.1M | −$27.8M |
| Operating margin | 17.6% | 12.0% | 5.8% | 5.9% | −4.6% | 9.1% | 10.3% | 8.6% | 4.0% | −3.3% |
| Net income | $68.5M | $51.6M | $27.5M | $15.5M | −$57.9M | $17.4M | $30.3M | $47.4M | −$48.8M | −$70.3M |
| Net margin | 11.0% | 7.4% | 3.6% | 2.0% | −7.8% | 2.1% | 3.5% | 5.3% | −6.0% | −8.3% |
| EPS (diluted) | $1.82 | $1.36 | $0.72 | $0.40 | −$1.49 | $0.43 | $0.73 | $1.07 | −$1.20 | −$1.70 |
| Balance sheet | ||||||||||
| Cash and equivalents | $36.5M | $83.3M | $51.9M | $29.9M | $100.6M | $144.6M | $89.4M | $152.6M | $168.7M | $145.0M |
| Total assets | $622.4M | $1.04B | $987.9M | $1.04B | $1.14B | $1.15B | $1.18B | $1.25B | $1.21B | $1.11B |
| Total liabilities | $86.1M | $649.9M | $548.5M | $580.2M | $673.7M | $651.0M | $637.7M | $668.6M | $670.4M | $620.8M |
| Long-term debt | $0 | $463.9M | $364.8M | $364.4M | $452.8M | $431.7M | $412.3M | $441.1M | $397.1M | $366.0M |
| Shareholders' equity | $526.0M | $379.0M | $426.2M | $444.9M | $451.7M | $483.3M | $533.4M | $567.7M | $529.1M | $472.6M |
| Cash flow | ||||||||||
| Operating cash flow | $74.2M | $75.2M | $85.3M | $71.9M | $13.2M | $92.6M | $16.9M | $108.4M | $47.3M | $41.7M |
| Capital expenditure | $28.9M | $20.2M | $20.4M | $19.8M | $23.5M | $15.1M | $21.3M | $20.7M | $26.9M | $22.9M |
| Free cash flow | $45.3M | $55.0M | $64.9M | $52.1M | −$10.3M | $77.5M | −$4.40M | $87.7M | $20.4M | $18.8M |
RevenueNet incomeNet margin (right axis, %)
| Q4 FY24†Sep 2024 | Q1 FY25Jan 2025 | Q2 FY25Apr 2025 | Q3 FY25Jul 2025 | Q4 FY25†Oct 2025 | Q1 FY26Jan 2026 | Q2 FY26Apr 2026 | Q3 FY26Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $205.7M | $199.8M | $212.9M | $203.0M | $228.9M | $209.6M | $216.0M | $210.5M |
| Growth (year over year) | −9.5% | +5.2% | +3.2% | −2.9% | +11.3% | +4.9% | +1.5% | +3.7% |
| Gross profit | $67.1M | $68.5M | $76.7M | $67.5M | $77.8M | $69.8M | $72.6M | $76.7M |
| Gross margin | 32.6% | 34.3% | 36.0% | 33.3% | 34.0% | 33.3% | 33.6% | 36.4% |
| Operating income | $10.9M | $11.2M | $22.1M | −$80.7M | $19.6M | $15.4M | $14.4M | $22.8M |
| Operating margin | 5.3% | 5.6% | 10.4% | −39.8% | 8.6% | 7.3% | 6.7% | 10.8% |
| Net income | −$51.1M | −$300.0K | $6.90M | −$89.1M | $12.2M | $2.30M | −$8.10M | $15.7M |
| Net margin | −24.8% | −0.2% | 3.2% | −43.9% | 5.3% | 1.1% | −3.8% | 7.5% |
| EPS (diluted) | −$1.25 | −$0.01 | $0.17 | −$2.15 | $0.29 | $0.05 | −$0.19 | $0.37 |
| Balance sheet | ||||||||
| Cash and equivalents | $168.7M | $176.0M | $205.1M | $136.4M | $145.0M | $119.5M | $85.3M | $99.2M |
| Total assets | $1.21B | $1.33B | $1.36B | $1.07B | $1.11B | $1.10B | $1.09B | $1.10B |
| Total liabilities | $670.4M | $778.0M | $793.7M | $603.9M | $620.8M | $607.2M | $601.3M | $589.5M |
| Long-term debt | $397.1M | $565.6M | $565.8M | $366.0M | $366.0M | $366.2M | $329.0M | $328.9M |
| Shareholders' equity | $529.1M | $540.2M | $549.7M | $455.3M | $472.6M | $476.9M | $474.2M | $496.6M |
| Cash flow | ||||||||
| Operating cash flow | $25.9M | $9.50M | $16.6M | $7.70M | $7.90M | −$16.1M | −$1.50M | $21.0M |
| Capital expenditure | $6.00M | $4.20M | $6.80M | $6.30M | $5.60M | $10.7M | $6.20M | $9.00M |
| Free cash flow | $19.9M | $5.30M | $9.80M | $1.40M | $2.30M | −$26.8M | −$7.70M | $12.0M |
From Varex Imaging Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in October. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Varex Imaging Corp
- Headquarters
- Salt Lake City, Utah From SEC filings, Oct 2026
Recent News (5)
-
Varex Imaging (VREX) Stock Jumps 50% on Teledyne (TDY) Buyout Deal Just as Its Turnaround Gains Traction
Varex Imaging (VREX) Stock Jumps 50% on Teledyne (TDY) Buyout Deal Just as Its Turnaround Gains Traction
-
Why Is Teledyne Technologies (TDY) Paying a 52% Premium for Varex (VREX)?
Why Is Teledyne Technologies (TDY) Paying a 52% Premium for Varex (VREX)?
-
Teledyne agrees to acquire Varex Imaging for $1.1bn Teledyne agrees to acquire Varex Imaging for $1.1bn
-
Teledyne inks $1.1B takeover of Varex Imaging Teledyne inks $1.1B takeover of Varex Imaging
-
Teledyne Technologies to Buy Varex Imaging for $1.1 Billion Teledyne Technologies to Buy Varex Imaging for $1.1 Billion
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International